Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center · Duke University · +4 more institutions
Abstract
Of 424 patients with ER/PgR-negative breast cancer, 12% tested AR-positive. The 6-month CBR was 19% [95% confidence interval (CI), 7%-39%] for bicalutamide. The median PFS was 12 weeks (95% CI, 11-22 weeks). Bicalutamide was well-tolerated with no grade 4/5 treatment-related adverse events observed.
AR was expressed in 12% of patients with ER/PgR-negative breast cancer screened for this trial. The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer.
Citation impact
- FWCI
- 16.63
- Percentile
- 100%
- References
- 39
Authors
22- AGAyca GucalpCorresponding
Memorial Sloan Kettering Cancer Center, Duke University, Cornell University, Dana-Farber Cancer Institute, Mayo Clinic in Florida
- SMSara M. Tolaney
Memorial Sloan Kettering Cancer Center, Duke University, Cornell University, Dana-Farber Cancer Institute, Mayo Clinic in Florida
- SJSteven J. Isakoff
Memorial Sloan Kettering Cancer Center, Duke University, Cornell University, Dana-Farber Cancer Institute, Mayo Clinic in Florida
- JNJames N. Ingle
Memorial Sloan Kettering Cancer Center, Duke University, Cornell University, Dana-Farber Cancer Institute, Mayo Clinic in Florida
- MCMinetta C. Liu
Memorial Sloan Kettering Cancer Center, Duke University, Georgetown University, Cornell University, Dana-Farber Cancer Institute, Mayo Clinic in Florida
Topics & keywords
- Bicalutamide
- Medicine
- Breast cancer
- Internal medicine
- Androgen receptor
- Oncology
- Antiandrogen
- Metastatic breast cancer
- Good health and well-being